Portage Biotech Bolsters Pipeline With Acquisition Of Four Adenosine Pathway-Targeting Candidates

Portage Biotech Inc  (NASDAQ: PRTG ) has agreed to acquire  Tarus Therapeutics , a private company developing adenosine receptor antagonists. Under the terms of the agreement, Portage will acquire Tarus for 2.4 million shares with the assumption of $3 million of liabilities.  Additionally, payments of up to $32 million would be triggered ... Full story available on Benzinga.com